Absci Q3 2026 Results: Net Loss of $33.3M, Loss Widens
Absci Corp reported a net loss for the third quarter of 2026 and continues to incur significant losses as it funds its Integrated Drug Creation platform and internal drug programs. As of October 30, 2026, the company had 172,745,810 shares of common stock outstanding and indicated a need for additional capital to fund future operations and clinical development.
- Key figure
- Net loss $33.3M